These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
482 related articles for article (PubMed ID: 23726266)
21. [Expression and clinical significance of plasma small RNA in patients with pancreatic cancer]. Pan W; Tang W; Yuan W; Yu Q; Zuo W; Xu C; Ma J Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):351-4. PubMed ID: 25030590 [TBL] [Abstract][Full Text] [Related]
22. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Martens-Uzunova ES; Jalava SE; Dits NF; van Leenders GJ; Møller S; Trapman J; Bangma CH; Litman T; Visakorpi T; Jenster G Oncogene; 2012 Feb; 31(8):978-91. PubMed ID: 21765474 [TBL] [Abstract][Full Text] [Related]
23. Plasma hTERT mRNA discriminates between clinically localized and locally advanced disease and is a predictor of recurrence in prostate cancer patients. March-Villalba JA; Martínez-Jabaloyas JM; Herrero MJ; Santamaría J; Aliño SF; Dasí F Expert Opin Biol Ther; 2012 Jun; 12 Suppl 1():S69-77. PubMed ID: 22559196 [TBL] [Abstract][Full Text] [Related]
25. [Quantitative detection of DD3 mRNA in prostate cancer tissues by real-time fluorescent quantitative reverse transcription polymerase chain reaction]. Tao ZH; Mao XL; Wang CH; Chen XD; Yu KY; Weng ZL; Hu YP; Zhang XH; Xie H; Wang OC; Song QT; Li CD; Chen ZG Zhonghua Nan Ke Xue; 2007 Feb; 13(2):130-3. PubMed ID: 17345768 [TBL] [Abstract][Full Text] [Related]
26. DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. Payne SR; Serth J; Schostak M; Kamradt J; Strauss A; Thelen P; Model F; Day JK; Liebenberg V; Morotti A; Yamamura S; Lograsso J; Sledziewski A; Semjonow A Prostate; 2009 Sep; 69(12):1257-69. PubMed ID: 19459176 [TBL] [Abstract][Full Text] [Related]
27. [Quantitative detection of differential display code 3 mRNA in peripheral blood of patients with prostate cancer]. Weng ZL; Yu KY; Mao XL; Tao ZH; Chen XD; Wu XL; Hu YP; Wang SQ; Li CD; Chen ZG Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(41):2911-5. PubMed ID: 17288789 [TBL] [Abstract][Full Text] [Related]
28. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709 [TBL] [Abstract][Full Text] [Related]
29. Molecular phenotyping of circulating tumour cells in patients with prostate cancer: prediction of distant metastases. Giesing M; Driesel G; Molitor D; Suchy B BJU Int; 2012 Dec; 110(11 Pt C):E1202-11. PubMed ID: 23046102 [TBL] [Abstract][Full Text] [Related]
30. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance. Avgeris M; Stravodimos K; Scorilas A Prostate; 2011 Dec; 71(16):1780-9. PubMed ID: 21520157 [TBL] [Abstract][Full Text] [Related]
31. Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy. Salonia A; Gallina A; Briganti A; Zanni G; Suardi N; Capitanio U; Colombo R; Bertini R; Freschi M; Guazzoni G; Rigatti P; Montorsi F BJU Int; 2011 Apr; 107(8):1243-9. PubMed ID: 20883480 [TBL] [Abstract][Full Text] [Related]
32. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. de Kok JB; Verhaegh GW; Roelofs RW; Hessels D; Kiemeney LA; Aalders TW; Swinkels DW; Schalken JA Cancer Res; 2002 May; 62(9):2695-8. PubMed ID: 11980670 [TBL] [Abstract][Full Text] [Related]
33. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Paci M; Maramotti S; Bellesia E; Formisano D; Albertazzi L; Ricchetti T; Ferrari G; Annessi V; Lasagni D; Carbonelli C; De Franco S; Brini M; Sgarbi G; Lodi R Lung Cancer; 2009 Apr; 64(1):92-7. PubMed ID: 18804892 [TBL] [Abstract][Full Text] [Related]
34. Use of two gene panels for prostate cancer diagnosis and patient risk stratification. Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133 [TBL] [Abstract][Full Text] [Related]
35. The combination of circulating long noncoding RNAs AK001058, INHBA-AS1, MIR4435-2HG, and CEBPA-AS1 fragments in plasma serve as diagnostic markers for gastric cancer. Ke D; Li H; Zhang Y; An Y; Fu H; Fang X; Zheng X Oncotarget; 2017 Mar; 8(13):21516-21525. PubMed ID: 28423525 [TBL] [Abstract][Full Text] [Related]
36. Elevated serum-circulating RNA in patients with conventional renal cell cancer. Feng G; Li G; Gentil-Perret A; Tostain J; Genin C Anticancer Res; 2008; 28(1A):321-6. PubMed ID: 18383864 [TBL] [Abstract][Full Text] [Related]
37. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Cao DL; Ye DW; Zhang HL; Zhu Y; Wang YX; Yao XD Prostate; 2011 May; 71(7):700-10. PubMed ID: 20957673 [TBL] [Abstract][Full Text] [Related]
38. The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting. Adam A; Engelbrecht MJ; Bornman MS; Manda SO; Moshokoa E; Feilat RA BJU Int; 2011 Dec; 108(11):1728-33. PubMed ID: 21507188 [TBL] [Abstract][Full Text] [Related]
39. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Fang C; Zhu DX; Dong HJ; Zhou ZJ; Wang YH; Liu L; Fan L; Miao KR; Liu P; Xu W; Li JY Ann Hematol; 2012 Apr; 91(4):553-9. PubMed ID: 21987025 [TBL] [Abstract][Full Text] [Related]